Abstract:
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
Abstract:
Methods for an improved culturing of the fungus Penicillium chrysogenum, in particular strain KIP 3201, for an optimised production of the anti-tumour natural compound sorbicillactone A (2), and derivatives thereof in large amounts as well as optimised methods for the recovery and purification thereof from the fungal biomass and from the culture medium are described. Furthermore, the biological activity of sorbicillactone A (2), and studies regarding the genotoxicity of the compound are described.
Abstract:
Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3 and A have the significance given in the specification are provided. The compounds can be used for the treatment or prevention of obesity.
Abstract:
Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
Abstract:
In a device for dosing and transporting dry urea, e.g., for implementing the SCR method in a motor vehicle, the device includes a storage vessel containing the dry urea in the form of pellets, the wall of the storage vessel having an opening to which a transport line is connected on the outer side. The device also includes a compressed air nozzle which is arranged inside the storage vessel at a distance from the opening, is oriented towards the opening, and may be supplied with compressed air, and a portioning element having an upper side oriented towards the inside of the storage vessel and a lower side opposite the wall of the storage vessel. At least one continuous channel having a larger cross section than the dimensions of the pellets connects the upper side and the lower side in order to form at least one receiving element for the pellets.
Abstract:
Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
Abstract:
The invention relates to substituted 5-benzyl-2,4-diaminopyrimidines of general formula (A) wherein R1 is C2-C3 alkyl an R2 is heterocyclyl, phenyl or naphthyl, bonded by one of its C-atoms and R3 is C2-C6 alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclysylfonyl, heterocyclylalkylsulfonyl or dialkylsulfamoyl; wherein alkyl, cycloalkyl and alyenyl can carry up to 6 carbon atoms alone or in compositions and can carry up to 6 ring members heterocyclically, alone, or in compositions and the groups R2 and R3 can be substituted; and to acid addition salts of compounds. The invention also relates to a method for producing the above 5-benzyl-2,4-diaminopyrimidines, to the intermediate. products that are produced, to corresponding medicaments and to the use of 5-benzyl-2,4-diaminopyrimidines as medicinal preparations. The products have antibiotic properties and are useful for combating or preventing infectious diseases.
Abstract:
Described is a spectacle lens comprising a region (distance portion) designed for viewing at large distances and in particular “to infinity”, a region (near portion) designed for viewing at short distances and in particular “reading distances”, and a progressive zone disposed between the distance portion and the near portion, in which the power of the spectacle lens increases from a value at a distance reference point located in the distance portion to a value at the near reference point located in the near portion along a curve (principal line) veering towards the nose. The invention is distinct in that the astigmatic deviation, i.e. the difference between the prescribed and the actual astigmatism along circles having a center lying 4 mm below the centration point and having a diameter of 10 to 40 mm satisfies the following conditions: two local minima occur which on a “right-hand side spectacle lens” are located at 95°±10° (according to TABO) and at 280°±10°, and on a “left-hand side spectacle lens” at 85°±10° and 260°±10°; and two local maxima occur which on both a “right-hand side spectacle lens” and also a “left-hand-side spectacle lens” are located at 215°±10° and 335°±10°.
Abstract:
An x-ray tube has a rotating anode and a high-voltage plug for attachment at a high-voltage terminal at a vacuum housing of the x-ray tube. The high-voltage plug contains a cooling channel for coolant which opens up into a channel provided in the shaft of the rotating anode. The cooling channel extends through the high-voltage plug substantially in the direction of the center axis (axis of rotation) of the rotating anode.